mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus Abstract #1086

Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.
Aim(s): To investigate the effect of Eve, a mTOR inhibitor, on cell viability and apoptosis activation in pNETs and identify possible markers of the efficacy of mTOR inhibitors that may help in identifying the patients who may benefit from treatment with mTOR inhibitors.
Materials and methods: 20 pNET primary cultures were treated with IGF1 and/or Eve. Cell viability and caspase activity were evaluated. Alpha Screen Assays for PI3K/AKT/mTOR pathway components were performed.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, Everolimus, mTOR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1089 Role of TGF beta-1 in Regulating Pancreatic Neuroendocrine Tumor Cell Viability
Introduction: Neuroendocrine tumors (NETs) are heterogeneous neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The role of transforming growth factor beta-1 (TGF b-1) in NET biology is largely unknown. TGF b-1 signaling pathway is tumor suppressive in most non-transformed epithelial cell lines. In contrast, many human carcinomas are refractory to the growth–inhibitory effects of TGF b-1.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, TGF-b1, Everolimus
#1090 p27kip1 Is Involved in the Resistance of Human Bronchial Carcinoids to m-TOR Inhibitors
Introduction: Bronchial carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that the typical BC human cell line NCI-H727 is sensitive to Everolimus (E), in terms of cell viability reduction, with a G0 cell-cycle arrest, while the atypical human BC cell line NCI-H720 is not. The mechanisms underlying this phenomenon have not been clarified
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Master Degree Katiuscia Benfini
Keywords: RAD001, BC, p27kip1, Cell cycle
#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: MASTER DEGREE Katiuscia Benfini
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova